Pharmaceutical CDMO Market To Witness Rapid Development
Pharmaceutical CDMO Industry
The global pharmaceutical CDMO market size is anticipated to reach USD 235.5 billion by 2030 and it is projected to grow at a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. A growing consumption of biopharmaceuticals, rising demand for advanced therapeutics, demand for orphan drug discovery, upsurge number of clinical trials and increasing demand for one-stop-shop CDMOS are anticipated to influence the global market positively.
In addition, increasing pharmaceutical R&D investments can drive the market growth. As pharmaceutical companies invest more in R&D, they may seek external expertise and resources to accelerate drug development processes. CDMOs provide specialized services in drug development, manufacturing, and testing, making them valuable partners for pharmaceutical companies looking to outsource certain aspects of their R&D activities. Several players are investing in R&D activities of pharmaceuticals. For instance, in 2022, F. Hoffmann La Roche increased its R&D spending to USD 14.7 billion from USD 13.3 billion in the previous year. Another major player in pharmaceutical R&D expenditures for the same period was Merck & Co., allocating USD 13.5 billion to R&D. Janssen, the pharmaceutical arm of Johnson & Johnson, followed with an investment of USD 11.6 billion, slightly lower than the previous year's USD 11.9 billion.
Besides, increasing outsourcing services by pharmaceutical companies in the pharmaceutical industry has profoundly impacted the market. The trend of outsourcing activities in pharmaceutical domain is rising as companies find value in acquiring additional competencies essential for successful drug development & commercialization. Besides providing extended expertise & assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks.
Notably, in the context of early-stage technologies and products, establishing expensive in-house capabilities entails substantial risks across product development phases. At the same time, outsourcing serves as a risk-averse alternative. In addition, having a limited understanding of the required scale for current & future product offerings or market penetration poses significant hurdles in designing and scaling manufacturing for in-house production. Consequently, the preference for outsourcing has grown as an effective strategy until market demand for products becomes well-established & understood.
Gather more insights about the market drivers, restrains and growth of the Global Pharmaceutical CDMO market
Pharmaceutical CDMO Market Segments Highlights:
- Based on product, the active pharmaceutical ingredient (API) segment led the market with the largest revenue share of 81.20% in 2023. The segment growth is driven by competitive drug development and growing demand for end-to-end Contract Development & Manufacturing Organization (CDMO) services. In addition, advancements in API manufacturing, growth of the biopharmaceutical sector, and increasing geriatric population are some of the key factors propelling segment growth
- Based on the workflow, the commercial segment held the largest market share in 2023 attributed to robust demand for pharmaceutical products, such as biosimilar medications, generic medications, and regenerative therapies. This is where commercial CDMOs may help by providing knowledge, saving time, and being cost-effective
- Based on application, the oncology segment dominated the market with the largest revenue share of 21.82% in 2023. The segment is driven by an increasing number of cancer cases globally. In addition, increasing pharmaceutical R&D investments, patent expirations, and demand for oncology drugs & biologic innovations are the factors driving the oncology market
Pharmaceutical CDMO Market Report Segmentation
Grand View Research has segmented the pharmaceutical CDMO market report based on product, workflow, application, end-use, and region:
Pharmaceutical CDMO Product Outlook (Revenue, USD Million, 2018 - 2030)
- API
- Type
- Synthesis
- Drug
- Manufacturing
- Drug Product
- Oral solid dose
- Semi-solid dose
- Liquid dose
- Others
Pharmaceutical CDMO Workflow Outlook (Revenue, USD Million, 2018 - 2030)
- Clinical
- Commercial
Pharmaceutical CDMO Application Outlook (Revenue, USD Million, 2018 - 2030)
- Oncology
- Infectious Diseases
- Neurological Disorders
- Cardiovascular Disease
- Metabolic Disorders
- Autoimmune Diseases
- Respiratory Diseases
- Ophthalmology
- Gastrointestinal Disorders
- Hormonal Disorders
- Hematological Disorders
- Others
Pharmaceutical CDMO End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Small Pharmaceutical Companies
- Medium Pharmaceutical Companies
- Large Pharmaceutical Companies
Pharmaceutical CDMO Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Key Pharmaceutical CDMO Company Insights
- Lonza
- Thermo Fisher Scientific, Inc.
- Recipharm AB
- Laboratory Corporation of America Holdings (LabCorp)
- Catalent, Inc.
- WuXi AppTec, Inc.
- Samsung Biologics
- Piramal Pharma Solutions
- Siegfried Holding AG
- CordenPharma International
- Cambrex Corporation
- Bushu Pharmaceuticals Ltd.
- Nipro Corporation
Order a free sample PDF of the Pharmaceutical CDMO Market Intelligence Study, published by Grand View Research.
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Spellen
- Gardening
- Health
- Home
- Literature
- Music
- Networking
- Other
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness
- IT, Cloud, Software and Technology
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Italiano
Russian
Romaian